SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
SEC Accession No. 0001193125-23-283535
Filing Date
2023-11-28
Accepted
2023-11-27 21:24:25
Documents
1
Group Members
ATHYRIUM FUNDS GP HOLDINGS LLCATHYRIUM OPPORTUNITIES ASSOCIATES IV CO-INVEST LLCATHYRIUM OPPORTUNITIES ASSOCIATES IV GP LLCATHYRIUM OPPORTUNITIES ASSOCIATES IV LPATHYRIUM OPPORTUNITIES IV CO-INVEST 2 LPJEFFREY A. FERRELL

Document Format Files

Seq Description Document Type Size
1 SC 13D/A d591619dsc13da.htm SC 13D/A 130688
  Complete submission text file 0001193125-23-283535.txt   132714
Mailing Address 400 CROSSING BOULEVARD BRIDGEWATER NJ 08807
Business Address 400 CROSSING BOULEVARD BRIDGEWATER NJ 08807 9088091300
RVL Pharmaceuticals plc (Subject) CIK: 0001739426 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L2 | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-90830 | Film No.: 231441719
SIC: 2834 Pharmaceutical Preparations

Mailing Address 505 FIFTH AVENUE FLOOR 18 NEW YORK NY 10017
Business Address 505 FIFTH AVENUE FLOOR 18 NEW YORK NY 10017 212-402-6925
Athyrium Opportunities IV Acquisition 2 LP (Filed by) CIK: 0001888848 (see all company filings)

IRS No.: 872028841 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A